Quince Therapeutics to Participate at Upcoming Investor Conferences
Quince Therapeutics (Nasdaq: QNCX), a late-stage biotechnology company focusing on rare diseases, has announced its participation in three upcoming investor conferences: 1.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
- 2024 Maxim Healthcare Virtual Summit – Quince’s Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3:00 p.m. Eastern Time. Qualified investors can register here to access the live event.
- LD Micro Main Event XVII – Quince’s Chief Operating Officer and Chief Business Officer Brendan Hannah will present a company overview on Tuesday, October 29, 2024 beginning at 6:30 p.m. Eastern Time. Please register here to access the live presentation.
- The ThinkEquity Conference 2024 – Quince’s President Charles Ryan, J.D., Ph.D., will present a company overview on October 30, 2024 beginning at 3:00 p.m. Eastern Time. A webcast of the presentation will be accessible here on the Events page of Quince’s Investor Relations website.
About Quince Therapeutics
Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, X, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241014846322/en/
Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com
Source: Quince Therapeutics, Inc.